Shire Buys Pfizer's IBD MAdCAM-1 Candidate For Undisclosed Price
Back on the product trail after its mega merger with Baxalta Inc, Shire PLC has bought global rights to Pfizer Inc.'s investigational biologic PF-00547659 for inflammatory bowel disease.
You may also be interested in...
Biogen Idec has confirmed that there have been 10 more cases of the rare brain viral infection, progressive multifocal leukoencephalopathy (PML), among multiple sclerosis patients taking Tysabri (natalizumab), a medication that it co-markets with Elan, bringing the total number of confirmed cases to 95 as of 2 February.
Evotec’s multimodality approach to drug discovery landed the biotech two new discovery collaborations this week, underscoring its emphasis on patient-driven data.
Novo Nordisk and Evotec will identify and develop novel drugs for treating chronic kidney disease, using datasets of CKD patients provided by the Danish group and from other sources.